PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.42%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-49.76%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-230.13%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-230.13%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-185.65%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-184.62%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-184.62%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
1.23%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.23%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-1.21%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
392.44%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
131.24%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-15.41%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-28.11%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-17.91%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1951.34%
10Y OCF/share CAGR above 1.5x AVGO's 441.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
200.68%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
65.62%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
12.15%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-319.46%
Negative 5Y net income/share CAGR while AVGO is 651.30%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-430.85%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
352.70%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
150.63%
5Y equity/share CAGR is in line with AVGO's 147.32%. Walter Schloss would see parallel mid-term profitability and retention policies.
85.64%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
-79.28%
Cut dividends over 10 years while AVGO stands at 1441.93%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-2.78%
Negative 5Y dividend/share CAGR while AVGO stands at 71.80%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-2.08%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-14.48%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-8.31%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.13%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-3.76%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-2.28%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.62%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
14.94%
SG&A growth well above AVGO's 14.12%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.